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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER337Pregnancy in Patients With Pre-Existing CardiomyopathiesKathleen Stergiopoulos, Elaine Shiang, Travis Bench
The distinct hemodynamic alterations of pregnancy, labor, and delivery pose unique risks to
women with pre-existing cardiomyopathies. Stergiopoulos and colleagues review how the
changes in intravascular volume, cardiac output, and peripheral vascular resistance can
exacerbate the pathophysiology in patients with impaired ventricular reserve due to either
dilated cardiomyopathy or hypertrophic cardiomyopathy. A multidisciplinary team approach
and a controlled delivery are crucial. Pre-conception planning and risk assessment are
essential, and proper counseling should be offered to expectant mothers regarding both the
risks that pregnancy poses and the implications for future offspring.CLINICAL RESEARCH INVASIVE CARDIOLOGY351It Is Safe to Defer Revascularization for Left Main Lesions With MLA >6 mm2Jose M. de la Torre Hernandez, Felipe Herna´ndez Hernandez, Fernando Alfonso, Jose R. Rumoroso,
Ramon Lopez-Palop, Mario Sadaba, Pilar Carrillo, Juan Rondan, Iñigo Lozano, Juan M. Ruiz Nodar,
Jose A. Baz, Eduard Fernandez Nofrerias, Fernando Pajin, Tamara Garcia Camarero, Hipolito Gutierrez,
on behalf of the LITRO Study Group (Spanish Working Group on Interventional Cardiology)
Angiography has important limitations in the evaluation of left main coronary artery
(LMCA) lesions with intermediate severity. de la Torre Hernandez and colleagues performed
a prospective study testing whether revascularization can be safely deferred in patients with a
minimum lumen area (MLA) 6 mm2, as assessed by intravascular ultrasound (IVUS),
regardless of angiographic severity. A total of 354 patients from 22 centers were followed.
LMCA revascularization was performed in 90% of patients with an MLA 6 mm2 and was
deferred in 96% of patients with an MLA 6 mm2. Two-year cardiac death-free survival was
98% in the deferred group versus 94% in the revascularized group, and only 4.4% of patients
in the deferred group required subsequent LMCA revascularization. An MLA 6 mm2 is a
safe value for deferring revascularization of the LMCA, and IVUS should be used for
intermediate-severity LMCA lesions.(continued on page A-24)
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uINVASIVE CARDIOLOGY359Simulator-Based Training May Improve the Performance of Transseptal CatheterizationRoberto De Ponti, Raffaella Marazzi, Sergio Ghiringhelli, Jorge A. Salerno-Uriarte, Hugh Calkins,
Alan Cheng
De Ponti and colleagues tested the utility of a virtual reality simulator for teaching
electrophysiology fellows how to perform transseptal catheterization (TSP-C). Fellows
inexperienced in TSP-C were enrolled and were randomly assigned to conventional training
with an experienced proctor or simulator-based training. Training time was significantly
longer for conventional training, and these fellows also had significantly lower post-training
performance scores and a higher number of recurrent errors. Simulator-based training may
improve subsequent TSP-C performance.CORONARY ARTERY DISEASE364Both Traditional Risk Factors and CAC Score Stratify Risk in Subjects With Low LDL-CRon Blankstein, Matthew J. Budoff, Leslee J. Shaw, David C. Goff, Jr, Joseph F. Polak, Joao Lima,
Roger S. Blumenthal, Khurram Nasir
Blankstein and colleagues used data from the MESA (Multi-Ethnic Study of Atherosclerosis)
to see which risk factors would identify patients at risk for coronary heart disease (CHD)
despite a low-density lipoprotein cholesterol (LDL-C) 130 mg/dl. All subjects underwent a
easurement of coronary artery calcium (CAC) and carotid intima media thickness (CIMT).
ndependent predictors of CHD in those with low LDL-C included age, male sex,
ypertension, diabetes, and low high-density lipoprotein cholesterol. After accounting for all
raditional risk factors, the predictive value of CAC was highly significant, but CIMT was
ot. Among individuals with LDL-C 130 mg/dl, the traditional cardiac risk factors still are
seful, and CAC screening can help to identify the highest-risk subjects.HEART FAILURE375BUN Concentration May Be a Marker for Adverse Effects of Loop DiureticsJeffrey M. Testani, Thomas P. Cappola, Colleen M. Brensinger, Richard P. Shannon, Stephen E. Kimmel
Testani and colleagues investigated whether blood urea nitrogen (BUN) levels could identify
patients with chronic systolic heart failure at increased risk for adverse outcomes and the
interactions with the use of high-dose loop diuretics (HDLDs). Using data from the BEST
(Beta-Blocker Evaluation of Survival Trial), HDLD use (defined as 160 mg/day of
furosemide equivalents) was associated with increased mortality; however, this association did
not persist after adjustment for baseline risk factors. In subjects with BUN levels above the
median (21.0 mg/dl), the adjusted risk for death was higher in the HDLD group and was
lower in those with BUN levels below the median. The risk associated with HDLD can be
assessed by BUN levels; the authors propose that high BUN levels are a marker of
neurohormonal activation stimulating BUN reabsorption in the proximal tubule.
Editorial Comment: JoAnn Lindenfeld, Robert W. Schrier, p. 383(continued on page A-28)
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wHEART FAILURE386sFlt-1 Provides Prognostic Information in Patients With Chronic HFBonnie Ky, Benjamin French, Kosha Ruparel, Nancy K. Sweitzer, James C. Fang, Wayne C. Levy,
Douglas B. Sawyer, Thomas P. Cappola
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor family
and may modulate vascular remodeling in chronic heart failure (HF). PlGF activates the
Fms-like tyrosine kinase receptor 1 (Flt-1), which is expressed in endothelial and renal
mesangial cells. Ky and colleagues investigated PlGF and soluble Fms-like tyrosine kinase 1
(sFlt-1) as clinical biomarkers in chronic HF. sFlt-1 was independently associated with
measures of HF severity, including New York Heart Association functional class and B-type
natriuretic peptide. Patients in the highest quartile of sFlt-1 had a 6.2-fold increased risk of
adverse outcomes. Combined assessment of sFlt-1 and BNP provided greater discrimination
compared with either marker alone. These findings support a role for sFlt-1 as a biomarker
for patients with chronic HF and suggest a role in the pathophysiology of HF.HEART RHYTHM DISORDERS395A New Risk Scheme to Predict Warfarin-Associated HemorrhageMargaret C. Fang, Alan S. Go, Yuchiao Chang, Leila H. Borowsky, Niela K. Pomernacki,
Natalia Udaltsova, Daniel E. Singer
Fang and colleagues used a database of almost 10,000 subjects with chronic atrial fibrillation
to develop a risk stratification score to predict warfarin-associated hemorrhage. There were
461 first major hemorrhages during follow-up (1.4% annually). Five independent variables
were found to predict bleeding risk: anemia (3 points), severe renal disease (e.g., glomerular
filtration rate 30 ml/min or dialysis-dependent, 3 points), age 75 years (2 points), prior
leeding (1 point), and hypertension (1 point). Collapsed into a 3-category risk score, major
emorrhage rates were 0.8% in the low-risk group (0 to 3 points), 2.6% in the intermediate-
isk group (4 points), and 5.8% in the high-risk group (5 to 10 points). This simple 5-
ariable risk score effectively quantifies the risk of warfarin-associated hemorrhage in patients
ith atrial fibrillation.(continued on page A-30)
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402ssociation Between Myocardial Fibrosis and Outcomes
in Patients With Low-Gradient Aortic Valve StenosisSebastian Herrmann, Stefan Störk, Markus Niemann, Volkmar Lange, Jörg M. Strotmann, Stefan Frantz,
Meinrad Beer, Stefan Gattenlöhner, Wolfram Voelker, Georg Ertl, Frank Weidemann
This prospective cohort study in patients with aortic stenosis (AS) aimed to identify
surrogates of myocardial fibrosis that help to differentiate low-gradient severe AS from
moderate AS and the impact of fibrosis on clinical outcomes. A total of 86 patients were
divided into 4 groups according to aortic valve area (AVA) (1.0 cm2), mean valve gradient,
and ejection fraction (EF). At baseline, a significant reduction of mitral ring displacement and
systolic strain-rate was detected in patients with low-gradient AS. These patients also had a
higher degree of interstitial fibrosis in biopsies and more segments with late-gadolinium
enhancement. Clinical outcomes were worse in patients with low-gradient severe AS and an
EF 50%. In severe AS, a low gradient is associated with a higher degree of fibrosis, reduced
ongitudinal function, and poorer clinical outcome, despite preserved EF.ditorial Comment: Philippe Pibarot, Jean G. Dumesnil, p. 413CARDIAC IMAGING416High-Intensity Signals in Carotid Plaques on MRI Predict Future Cardiac EventsTeruo Noguchi, Naoaki Yamada, Masahiro Higashi, Yoichi Goto, Hiroaki Naito
Noguchi and colleagues have previously shown that noncontrast T1-weighted imaging
(magnetization-prepared rapid acquisition with gradient echo [MPRAGE]) can identify
vulnerable carotid plaques that have high-intensity signals. In this report, the risk of future
cardiac events in patients with known coronary artery disease (CAD) and carotid high-
intensity plaque (HIP) was compared with those with no HIP. The presence of HIP was
significantly associated with cardiac events, with multivariate Cox regression analysis
identifying the presence of HIP as the strongest independent predictor of cardiac events
(hazard ratio: 3.10). Characterization of carotid plaques using MPRAGE provides clinically
relevant information for the risk assessment of CAD patients.
Editorial Comment: Chun Yuan, Nayak L. Polissar, Thomas S. Hatsukami, p. 423(continued on page A-34)
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Noel Burtt, Benjamin Voight, Marco Tubaro, Flora Peyvandi, Marta Spreafico, Patrizia Celli,
Daniela Lina, Maria Francesca Notarangelo, Maurizio Ferrario, Raffaela Fetiveau, Giorgio Casari,
Michele Galli, Flavio Ribichini, Marco L. Rossi, Francesco Bernardi, Nicola Marziliano, Pietro Zonzin,
Francesco Mauri, Alberto Piazza, Luisa Foco, Luisa Bernardinelli, David Altshuler, Sekar Kathiresan,
on behalf of the Italian Atherosclerosis, Thrombosis and Vascular Biology Investigators
9p21.3 genetic variants may influence the risk of ischemic heart disease. Ardissino and
colleagues tested whether the 9p21.3 variant rs1333040 influences the occurrence of new
cardiovascular events and coronary atherosclerosis progression in patients who experienced a
first myocardial infarction prior to age 45 years. Over 16,599 person-years, the rs1333040
genotype had a significant influence on the primary endpoint, with an adjusted hazard ratio
of 1.19 for heterozygous carriers and 1.41 for homozygous carriers. This was mostly driven by
increased rates of coronary revascularization. It also significantly influenced the rate of
coronary atherosclerosis progression in patients who had at least 2 angiograms.Editorial Comment: Joseph B. Muhlestein, Jeffrey L. Anderson, p. 435
